rAAV vectors increase cardiac-specific expression of RNR and elevate cardiomyocyte 2-dATP levels.
D
uchenne muscular dystrophy (DMD) and its milder and allelic form, Becker muscular dystrophy (BMD), are the most frequent muscular dystrophies, occurring once in w5,000 male births, and are due to mutations in the dystrophin gene (1) . DMD patients typically die due to cardiac and respiratory muscle failure; thus, maintenance of adequate function in both cardiac and skeletal muscle is critical for optimal DMD therapy. The primary function of dystrophin is to provide a structural role by mechanically linking the subsarcolemmal cytoskeleton to the extracellular matrix through the dystrophin-glycoprotein complex (DGC) (2) . This linkage transmits the forces of contraction to the extracellular matrix and protects muscles from contraction-induced injury (3) (4) (5) (6) (7) . In addition to a structural or mechanical role, the DGC also serves as a scaffold for cytoplasmic and membraneassociated signaling proteins and ion channels (8) (9) (10) (11) . The complete absence of dystrophin results in drastic reductions of all DGC components (12) (13) (14) .
Together, an absence of dystrophin and reduction in the DGC components causes membrane destabilization and permeability defects that lead to myofiber degeneration, repeated cycles of degeneration/regeneration, and the gradual replacement of muscle fibers with fibrotic, connective, and adipose tissue.
In contrast, some in-frame deletions, truncations, and missense mutations lead to reduced dystrophin expression associated with milder phenotypes. These (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . In mdx mice, muscle pathology is milder than in humans, with the exception of the diaphragm; however, the dystrophic phenotype worsens with increasing age including the development of cardiac dysfunction (25) (26) (27) (28) (29) (30) (31) (32) . Administration of recombinant adeno-associated viral (rAAV)-mediated mDys therapy in mdx mice preceding the onset of cardiomyopathy is highly cardioprotective (33) (34) (35) . However, when mdx mice are treated with mDys at a late stage of cardiomyopathy, such as would be the case for a number of DMD patients, a full rescue of the dysfunctional cardiac phenotype is not achieved (30, (35) (36) (37) .
We have developed a cardiac function-enhancing gene therapy approach that targets myosin in contractile filaments by overexpressing the enzyme ribonucleotide reductase (RNR). RNR converts adenosine diphosphate (ADP) to deoxy-ADP (dADP), which is rapidly converted to deoxy-adenosine triphosphate (dATP) in cells. In numerous in vitro studies, we have shown that dATP increases cross-bridge binding and cycling, resulting in stronger, faster contraction and faster relaxation (38) (39) (40) (41) (42) (43) (44) (45) . We have also reported that dATP improves contractile properties of myocardium from end-stage human heart failure (HF) in vitro (42) and dogs with end-stage idiopathic dilated cardiomyopathy (46) . In normal rodent muscle, we reported that increases in cardiomyocytes and cardiac function occur with as little as w1% of the ATP pool in the dATP form (40, 47 (generated in-house) mice were used for these studies (17) . All animals were experimentally manipulated in accordance with the Institutional Animal Care and Use Committee of the University of Washington.
Experimental mice were administered vector at 22 to 24 months of age via the retro-orbital sinus with a 200-ml bolus injection in Hanks balanced saline solution at a dose of 2 Â 10 14 vg/kg. All mice were housed in a specific-pathogen free animal care facility using a 12-h light/12-h dark cycle with access to food and water ad libitum.
VECTOR PRODUCTION. rAAV genomes containing the CK8 regulatory cassette (expressed exclusively in skeletal and cardiac muscle) and the human codon optimized (GenScript) mDys (DR2-15/DR18-22/DCT) (24), followed by the rabbit beta-globin poly-adenylation (pA) signal, were generated using standard cloning techniques. The rAAV genomes containing the cardiac muscle-specific cTnT455 regulatory cassette, the codon optimized human RNR transgene flanked by 100-bp untranslated regions, and the rabbit beta-globin pA were generated as previously described (48) . The "dead" rAAV genomes or promoter-less firefly luciferase followed by the human growth hormone (hGH) pA (kindly provided by J.S.C., University of Washington, Seattle, Washington)
were used to generate the control rAAV genomes. The resulting constructs were cotransfected with the pDG6 packaging plasmid into HEK293 cells to
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Nucleotide-Based Cardiac Gene Therapy Restores Function in dmd Mice Horseradish-peroxidase conjugated secondary antibody staining (1:50,000) was performed for 1 h at room temperature before signal development using Clarity
Western ECL substrate (BioRad) and visualization using a Chemidoc MP imaging system (BioRad).
QUANTIFICATION OF CARDIAC dATP. Approximately 25 mg of flash frozen, freshly ground ventricle
Nucleotide-Based Cardiac Gene Therapy Restores Function in dmd Mice cardiac tissue was used for direct quantification of intracellular dATP using the high-performance liquid chromatography (HPLC)-with tandem mass spectrometry (MS/MS) method previously described (50).
Briefly, samples were extracted 1 to 3 days before measurement using a 50% methanol solution. in the isolated perfused heart preparation. The LVSP response to increased preload was significantly improved in both in mdx 4cv þRNR and mdx 4cv þmDys hearts compared to mdx 4cv ( Figure 2A) . However, only RNR treatment improved the diastolic response in mdx 4cv hearts, to levels similar to WT ( Figure 2B ).
Both contractility and relaxation (i.e., þdP/dt and Kolwicz, Jr., et al.
-dP/dt, respectively) were impaired in mdx short-term physiologic increase in cardiac work (47, 48) . To verify that the improved systolic and diastolic function in RNR-treated mdx 4cv hearts at baseline was not associated with an inability to respond to an increased energetic demand, we stressed hearts with a combination of high calcium and elevated heart rates, via pacing stimulation. As shown in Figures 3A and 3B, mdx 4cv hearts had a blunted response to the increased workload as both LVDevP and RPP were w25% to 30% lower than WT hearts. In addition, both þdP/dt and -dP/dt were impaired in mdx 4cv relative to WT hearts ( Figures 3C and 3D) . Systolic parameters in mdx 4cv þmDys hearts were effectively improved and similar to age-matched WT hearts for the entire duration of the workload challenge RC ¼ regulatory cassette; WT ¼ wild-type.
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( Figures 3A to 3C) . Measures of systolic function significantly increased in mdx 4cv þ RNR hearts during the initial half of the high workload protocol and remained w15% higher than mdx 4cv ( Figures 3A to 3C ).
Interestingly, -dP/dt values tended to be elevated only in mdx 4cv þ RNR hearts during the physiologic challenge ( Figure 3D ). These data show that both RNR and mDys treatments improve systolic function in mdx 4cv hearts without compromising cardiac reserve.
Combined with the baseline and pressure-volume relationship assessments, our data show that, in addition to the systolic enhancements, RNR has an added benefit of improving diastolic function.
RNR AND mDys TRANSDUCTION, EXPRESSION, AND CARDIOMYOCYTE LOCALIZATION.
To evaluate the localization of RNR and mDys protein within the hearts of mice, we performed immunofluorescence imaging.
As shown in Figure 4 , the RNR subunit (Rrm1) was robustly expressed in ventricles of RNR-treated mice.
The expression of mDys appeared to be saturated relative to full-length dystrophin levels, with both being properly localized to the sarcolemma of cardiomyocytes. We also evaluated general muscle histopathology and potential differences in myocardial fibrosis by Masson trichrome staining, and observed no discernable difference between treated or untreated mdx 4cv mice ( Figure 5 ). In addition, neither RNR nor mDys treatment significantly altered body weight, heart weight, or the heart weight-to-body weight ratio (Supplemental Figure 3) . Western blotting was performed to determine the extent of rAAV vector 6-mediated RNR and mDys protein expression profiles in ventricular tissue ( Figure 6 ). We observed mDys protein expression in ventricular tissue that approached levels similar to WT mice, whereas both human RNR subunits were found to be elevated to comparable levels within ventricular tissue ( Figure 6A) . To evaluate the relative proportions of Kolwicz, Jr., et al.
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DISCUSSION
In the present study, we used a novel gene therapy approach that targets myosin in the contractile fila- Hearts were isolated from mdx 4cv mice treated with control vector (mdx 4cv , n ¼ 6), ribonucleotide reductase (mdx 4cv þ RNR, n ¼ 6), or microdystrophin (mdx 4cv þ mDys, n ¼ 5). Age-matched, nondiseased, nontreated wild-type (WT) mice were used as control subjects (n ¼ 4).
All hearts were perfused with a glucose-pyruvate buffer containing high calcium (4.0 mmol/l) to simulate a high workload challenge for 20 min. Hearts were paced at 450 beats per minute throughout the protocol. . Abbreviations as in Figures 1 and 2 .
Nucleotide-Based Cardiac Gene Therapy Restores Function in dmd Mice muscle via inclusion of a modified cardiac-specific enhancer/promoter derived from the human cTnT gene, which facilitates increases in myocyte contraction and cardiac performance in normal rodent hearts as well as in infarcted rodents and pig hearts (48, 53) .
Importantly, we previously showed that dATPproducing cells deliver it to surrounding myocardium by diffusion through gap junctions (54) , such that only a minority of cardiomyocytes needs to be transduced to have global benefits within the heart.
We now show that using this vector technology leads (57) and abnormal in vivo pressure-volume dynamics were observed in 22-month-old mdx mice (58).
Treatment of young male mdx mice with rAAV6 vector delivering cytomegalovirus (CMV) promoter/ enhancer driven microdystrophin did not correct the impairments in þdP/dt, -dP/dt, or LV systolic pressure when assessed at 5 months of age via hemodynamic analysis (35) . However, an improvement was noted for the preload recruited stroke work in mdx mice treated with mDys compared to untreated mdx or WT control subjects (35) .
In our current study, 27-month to 29-month-old mice were subjected to ex vivo assessment of cardiac function using the Langendorff isolated heart preparation, which is a century-old methodology with several advantages and limitations (59) . The perfusate used is similar to, but not the same as blood, and situations of physiologic challenge (e.g., Kolwicz, Jr., et al.
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Kolwicz, Jr., et al. collectively influence the clinical phenotype (69) . As an indication of the progressive nature of DMD cardiomyopathy, the estimated overall incidence of latent DCM is 25% by 6 years of age and 59% by 10 years of age in DMD patients (70) . As such, further evidence suggests latency in cardiac dysfunction at basal levels that becomes more pronounced with an induction of increased physiological demand.
Consistent with these observations, an impaired response to beta-adrenergic stimulation by either dobutamine or isoproterenol can be detected in mdx mice at 3 to 4 months of age (35, 71) . Exercise can because muscle-specific regulatory cassettes were used for expression of therapeutic proteins, we can surmise that <1% of protein expression would be generated from non-muscle cell types present in the heart, suggesting that the functional benefit was truly caused by cardiomyocyte transduction. As previously stated, the cTnT regulatory cassette drives RNR expression only in heart muscle, whereas the CK8 regulatory cassette drives mDys expression no selectively in both cardiac and skeletal muscle cells, but at only very low background levels in other tissues. This raises the possibility that the functional benefit of expressing mDys in skeletal muscles might increase energetic demands on the heart, thereby partially masking some of the mDys-derived cardiac functional benefits (37) . Because RNR delivery to DMD mice of advanced age increased cardiac function in the absence of RNR expression in skeletal muscle, and because over-expression of endogenous RNR should be nonimmunogenic, supplemental RNR therapy in conjunction with mDys therapy might be beneficial for DMD patients. Future studies are aimed at determining the extent of functional restoration by combining both RNR-and mDys-based therapies.
